ASCO 2025
CHICAGO
We are excited to be at ASCO 2025 to share our latest data, and engage and learn with the scientific community, solidifying our goal to bring the promise of cell therapy to as many eligible patients as possible.
To learn more about our cell therapy abstracts and data, please visit the congress website.
Transforming Science Within the Community
Join us to hear how Gilead's legacy has paved the way to an innovative approach for patient-centered oncology care.
In Exhibit Hall | Industry Expert Theater 1
MEET THE SPEAKERS
MODERATOR:
Darren Tayama, MD
Vice President
US Medical Affairs, Oncology
Gilead Sciences
PANELISTS
Staci Bush, PA
Senior Director, Scientific Collaboration
US Medical Affairs, Virology
Gilead Sciences
Timothy Best, PhD
Senior Director
Global Medical Affairs
Kite Pharma
Sabrina Meyers, PharmD
Senior Director, Head of Community Oncology Strategy
US Medical Affairs, Oncology
Gilead Sciences
Watch related videos
Charting a course in the CAR T age: SoC in 2L R/R DLBCL
Professor Fabio Ciceri
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
Reporting of side effects
If you get any side effects, talk to your doctor or nurse. In the United Kingdom, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.